A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

NCT06388187 · Completed

Last updated 2026-05-28

This study is testing different doses of the medication CagriSema in adults with obesity to see how well it helps them lose weight.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 300 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-06 · est. completion 2026-04

Where 25 sites · Canada, France, Germany, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT06388187 ↗

Description as written by the study sponsor.

This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.

Treatments tested

Cagrilintide Drug

Participants will receive once-weekly cagrilintide subcutaneously.
Semaglutide Drug

Participants will receive once-weekly semaglutide subcutaneously.
Placebo Drug

Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.

Main thing measured	Relative change in body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06388187 ↗